Visual morbidity in macroprolactinoma: A retrospective cohort study.
cabergoline
pituitary macroadenoma
prolactinoma
surgery
visual morbidity
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
18 Aug 2024
18 Aug 2024
Historique:
revised:
03
07
2024
received:
04
04
2024
accepted:
13
07
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
aheadofprint
Résumé
The management of visual field damage in patients with macroprolactinomas is a major therapeutic challenge. We aimed to study the visual morbidity associated with macroprolactinoma and its outcomes following medical and surgical treatment. We aimed to identify predictors of visual recovery. We retrospectively reviewed patient's data including clinical presentation, serial pituitary magnetic resonance imaging, laboratory tests, visual symptoms and neuro-ophthalmologic examination, visual field tests and optical coherence tomography tests. The main outcome was complete visual field recovery. Descriptive analyses were conducted. Predictors of visual recovery were investigated. The study cohort included 150 patients with macroprolactinoma [median follow-up, 6.0 years (interquartile range (IQR) 2.9-10.6)]. At diagnosis, visual field defects were evident in 40 patients (26.7%). At the end of follow-up, 24 out of 39 available visual field tests (61.5%) exhibited complete recovery. Patients that achieved complete visual recovery had smaller macroadenomas at diagnosis [30.5 mm (15.0-80.0) vs. 42.0 mm (30.0-85.0), p < .01], lower baseline serum prolactin levels [1414 mcg/L (489-3586) vs. 4119 mcg/L (2715-6315), p < .01], lower rates of central hypogonadism (78.3% vs. 93.3%, p = .05) and central hypothyroidism (20.8% vs. 53.3%, p = .04), lower rates of compressive optic neuropathy (35.3% vs. 87.5%, p = .02) and a better visual acuity (better than 6/8 in both eyes, 93.7% vs. 28.6%, p < .01). In our cohort of 150 patients with macroprolactinoma, 40 patients (26.7%) presented with visual field defects, of which 61.5% achieved complete visual recovery with treatment. Patients that achieved complete visual recovery presented with smaller macroadenomas, lower serum prolactin levels, lower rates of central hypogonadism and central hypothyroidism, lower rates of compressive optic neuropathy and better visual acuity.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Clinical Endocrinology published by John Wiley & Sons Ltd.
Références
Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377‐382. doi:10.1111/j.1365-2265.2009.03667.x
Mindermann T, Wilson CB. Age‐related and gender‐related occurrence of pituitary adenomas. Clin Endocrinol. 1994;41(3):359‐364. doi:10.1111/j.1365-2265.1994.tb02557.x
Lithgow K, Batra R, Matthews T, Karavitaki N. Management of endocrine disease: visual morbidity in patients with pituitary adenoma. Eur J Endocrinol. 2019;181(5):R185‐R197. doi:10.1530/EJE-19-0349
Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24‐month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89(4):1704‐1711. doi:10.1210/jc.2003-030979
Rudman Y, Duskin‐Bitan H, Manisterski Y, et al. Long‐term response to cabergoline and multi‐modal treatment in men with macroprolactinoma: does size really matter? Clin Endocrinol. 2021;95(4):606‐617. doi:10.1111/cen.14541
Hamidi O, Van Gompel J, Gruber L, et al. Management and outcomes of giant prolactinoma: a series of 71 patients. Endocr Pract. 2019;25(4):340‐352. doi:10.4158/EP-2018-0392
Chattopadhyay A, Bhansali A, Masoodi SR. Long‐term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary. 2005;8(2):147‐154. doi:10.1007/s11102-005-5111-4
Espinosa E, Sosa E, Mendoza V, Ramírez C, Melgar V, Mercado M. Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine. 2016;52(3):652‐659. doi:10.1007/s12020-015-0791-7
Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170(6):R213‐R227. doi:10.1530/EJE-14-0013
Baba MS, Islam Mir SU, Bhat MH, Laway BA, Misgar RA. Gender disparities in prolactinomas: unravelling clinical patterns, metabolic variations, and treatment responses. Cureus. 2023;15(8):e42911. doi:10.7759/cureus.42911
Duskin‐Bitan H, Shimon I. Prolactinomas in males: any differences? Pituitary. 2020;23(1):52‐57. doi:10.1007/s11102-019-01009-y
Crespo I, Santos A, Resmini E, Valassix E, Martínez‐Momblán MA, Webb SM. Improving quality of life in patients with pituitary tumours. Eur Endocrinol. 2013;9(1):32‐36. doi:10.17925/EE.2013.09.01.32
Andela CD, Lobatto DJ, Pereira AM, van Furth WR, Biermasz NR. How non‐functioning pituitary adenomas can affect health‐related quality of life: a conceptual model and literature review. Pituitary. 2018;21(2):208‐216. doi:10.1007/s11102-017-0860-4
Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13(2):220‐240. doi:10.1210/edrv-13-2-220
Jones SE, James RA, Hall K, Kendall‐Taylor P. Optic chiasmal herniation—an under recognized complication of dopamine agonist therapy for macroprolactinoma. Clin Endocrinol. 2000;53(4):529‐534. doi:10.1046/j.1365-2265.2000.01039.x
Raverot G, Jacob M, Jouanneau E, et al. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol. 2009;70(4):588‐592. doi:10.1111/j.1365-2265.2008.03364.x
Singh TD, Valizadeh N, Meyer FB, Atkinson JLD, Erickson D, Rabinstein AA. Management and outcomes of pituitary apoplexy. J Neurosurg. 2015;122(6):1450‐1457. doi:10.3171/2014.10.JNS141204
Park SH, Kang MS, Kim SY, et al. Analysis of factors affecting visual field recovery following surgery for pituitary adenoma. Int Ophthalmol. 2021;41(6):2019‐2026. doi:10.1007/s10792-021-01757-6
Moster ML, Savino PJ, Schatz NJ, Snyder PJ, Sergott RC, Bosley TM. Visual function in prolactinoma patients treated with bromocriptine. Ophthalmology. 1985;92(10):1332‐1341. doi:10.1016/s0161-6420(85)33853-8
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273‐288. doi:10.1210/jc.2010-1692
Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin‐secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol. 2023;19(12):722‐740. doi:10.1038/s41574-023-00886-5
Himonakos C, Burman P, Borg H, et al. Long‐term follow‐up of 84 patients with giant prolactinomas—a Swedish nationwide study. J Clin Endocrinol Metab. 2023;108(12):e1506‐e1514. doi:10.1210/clinem/dgad393
Butenschoen VM, Schwendinger N, von Werder A, et al. Visual acuity and its postoperative outcome after transsphenoidal adenoma resection. Neurosurg Rev. 2021;44(4):2245‐2251. doi:10.1007/s10143-020-01408-x
Galal A, Faisal A, Al‐Werdany M, El Shehaby A, Lotfy T, Moharram H. Determinants of postoperative visual recovery in suprasellar meningiomas. Acta Neurochir. 2010;152(1):69‐77. doi:10.1007/s00701-009-0492-1
Qiao N, Ma Y, Chen X, et al. Machine learning prediction of visual outcome after surgical decompression of sellar region tumors. J Pers Med. 2022;12(2):152. doi:10.3390/jpm12020152
Danesh‐Meyer HV, Papchenko T, Savino PJ, Law A, Evans J, Gamble GD. In vivo retinal nerve fiber layer thickness measured by optical coherence tomography predicts visual recovery after surgery for parachiasmal tumors. Invest Ophthalmol Vis Sci. 2008;49(5):1879‐1885. doi:10.1167/iovs.07-1127
Thotakura A, Patibandla M, Panigrahi M, Addagada G. Predictors of visual outcome with transsphenoidal excision of pituitary adenomas having suprasellar extension: a prospective series of 100 cases and brief review of the literature. Asian J Neurosurg. 2017;12(1):1‐5. doi:10.4103/1793-5482.149995
Möller‐Goede DL, Brändle M, Landau K, Bernays RL, Schmid C. Pituitary apoplexy: re‐evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome. Eur J Endocrinol. 2011;164(1):37‐43. doi:10.1530/EJE-10-0651
Sarwar KN, Huda MSB, Van de Velde V, et al. The prevalence and natural history of pituitary hemorrhage in prolactinoma. J Clin Endocrinol Metab. 2013;98(6):2362‐2367. doi:10.1210/jc.2013-1249
Capatina C, Inder W, Karavitaki N, Wass JAH. Management of endocrine disease: pituitary tumour apoplexy. Eur J Endocrinol. 2015;172(5):R179‐R190. doi:10.1530/EJE-14-0794
Chng E, Dalan R. Pituitary apoplexy associated with cabergoline therapy. J Clin Neurosci. 2013;20(12):1637‐1643. doi:10.1016/j.jocn.2013.02.027
Chen Z, Shou X, Ji L, et al. Presurgical medical treatment in prolactinomas: surgical implications and pathological characteristics from 290 cases. J Clin Endocrinol Metab. 2024;109:1433‐1442. doi:10.1210/clinem/dgad758
Menucci M, Quiñones‐Hinojosa A, Burger P, Salvatori R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary. 2011;14(1):68‐74. doi:10.1007/s11102-010-0261-4
Pecorari IL, Qama E, Akbar N, Colley P, Fang CH, Agarwal V. The effect of preoperative cabergoline on prolactinoma fibrosis: a case series. J Neurol Surg Rep. 2024;85(2):e66‐e73. Published 2024 May 15 doi:10.1055/s-0044-1786740
Banc A, Biousse V, Newman NJ, Kedar S. Ocular optical coherence tomography in the evaluation of sellar and parasellar masses: a review. Neurosurgery. 2023;92(1):42‐67. doi:10.1227/neu.0000000000002186